TT
Those 3 milestones were the ones mentioned at the AGM & in the annual report I believe.
The chances of any of those milestones being achieved in my opinion are remote at best.
(1) Take the FDA approval for bile duct. I would have thought the Company would have to run new trials for this to be approved? In any event it’s been a very long time that this has been discussed and very little progress to date that I have been able to read or find. Happy to be corrected but that’s how I see it.
(2) Australian reimbursement? No chance in my opinion. Not without FDA approval for pancreatic cancer. And that can’t happen without a huge fully funded trial. Not possible with only 6 months funding left.
(3) GBA approval? Maybe. But again it’s been delayed several times and I believe it was initially discussed over 2 years ago? Again, more than happy to be corrected but the only update we read is more hospitals that can negotiate funding with the company. This doesn’t sound like National reimbursement to me?
(4) Injectables? First patient dosed late last year. Haven’t heard anything since.
(5) Deal? Again what deal? It’s been a year since that was touted to what end I ask?
And yes, I can already hear Ozzie going into battle mode and about to start the record player again!!!
- Forums
- ASX - By Stock
- Why OSL is a Multi-Bagger
OSL
oncosil medical ltd
Add to My Watchlist
0.00%
!
$1.02

TTThose 3 milestones were the ones mentioned at the AGM & in the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.02 |
Change
0.000(0.00%) |
Mkt cap ! $14.43M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 294 | $1.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 27 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 294 | 1.050 |
1 | 15628 | 0.950 |
2 | 1349 | 0.940 |
1 | 627 | 0.920 |
2 | 623 | 0.910 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 27 | 1 |
1.050 | 25000 | 1 |
1.075 | 1879 | 1 |
1.080 | 48 | 1 |
1.090 | 375 | 1 |
Last trade - 07.04am 19/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
Day chart unavailable
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online